<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXAMETHASONE INTENSOL- dexamethasone solution, concentrate </strong><br>Carilion Materials Management<br></p></div>
<h1>DEXAMETHASONE Tablets USP, DEXAMETHASONE Oral Solution, and DEXAMETHASONE Intensol ™ Oral Solution (Concentrate)
        <br><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58e4e3e2-8f29-4b90-a446-700ddcf32e64"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_553eb112-caa0-475a-bc94-c0f9315349a3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dexamethasone Tablets 0.5, 0.75, 1, 1.5, 2, 4 and 6 mg USP, Dexamethasone Oral Solution, 0.5 mg per 5 mL and Dexamethasone ™ Oral Solution (Concentrate), 1 mg per mL are for oral administration.
                            <span class="Italics">Intensol</span></p>
<p>Each tablet contains:</p>
<p>Dexamethasone 0.5, 0.75, 1, 1.5, 2, 4, or 6 mg</p>
<p>Each 5 mL of Oral Solution contains:</p>
<p>Dexamethasone....................................................... 0.5 mg</p>
<p>Each mL of ™ Oral Solution (Concentrate) contains:
                            <span class="Italics">Intensol</span></p>
<p>Dexamethasone....................................................... 1 mg</p>
<p>Alcohol 30%</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_06934528-e209-419b-80c9-bcd196b6ed12"></a><a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<p class="First">The tablets contain lactose monohydrate, magnesium stearate, starch, sucrose, cosmetic ochre (1 mg), D&amp;C Yellow No. 10 (0.5, 4 mg), FD&amp;C Blue No. 1 (0.75, 1.5 mg), FD&amp;C Green No. 3 (4, 6 mg), FD&amp;C Red No. 3 (1.5 mg), FD&amp;C Red No. 40 (1.5 mg), and FD&amp;C Yellow No. 6 (0.5, 4 mg).</p>
<p>The oral solution contains citric acid, disodium edetate, flavoring, glycerin, methylparaben, propylene glycol, propylparaben, sorbitol and water.</p>
<p>The ™ oral solution contains alcohol, benzoic acid, citric acid, disodium edetate, propylene glycol, and water.
                                    <span class="Italics">Intensol</span></p>
<p>Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. The molecular formula is C H FO . The molecular weight is 392.47. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene,3,20-dione and the structural formula is:
                                    <span class="Sub">22</span><span class="Sub">29</span><span class="Sub">5</span></p>
<p><img alt="Structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a817ab46-54ec-4e3f-886b-04ce6ac1caf9&amp;name=b15200fb-1826-472b-a907-e677a272513b-01.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9c71419d-6ca0-4299-bbf1-a085f8f2418d"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs including dexamethasone are primarily used for their anti-inflammatory effects in disorders of many organ systems.</p>
<p>At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d0e2021e-3686-4730-ab5f-8c11c589cefb"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8bf441d-4bbe-4082-93bf-35edbb3be45e"></a><a name="section-4.1"></a><p></p>
<h2>Allergic States</h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions, perennial or <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02c5777b-15c6-4554-8404-66edc74141c7"></a><a name="section-4.2"></a><p></p>
<h2>Dermatologic Diseases</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis, exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, and severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e841809-0048-4930-9e9d-48d170ed6814"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></h2>
<p class="First">Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer, and nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49ddb744-4b7e-4e1e-98e6-ad87ba837cae"></a><a name="section-4.4"></a><p></p>
<h2>Gastrointestinal Diseases</h2>
<p class="First">To tide the patient over a critical period of the disease in <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_233d6802-3bdf-411a-8007-f5aaa6b07bbc"></a><a name="section-4.5"></a><p></p>
<h2>Hematologic Disorders</h2>
<p class="First">Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span> (Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> in adults, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, and selected cases of secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d61f19b2-b73a-44e5-ba7b-00fc57b0c5e2"></a><a name="section-4.6"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First">Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c183956-4f05-40b1-a47b-d6ba79c9f9ac"></a><a name="section-4.7"></a><p></p>
<h2>Neoplastic Diseases</h2>
<p class="First">For the palliative management of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e8147a3-1630-4098-952f-28703a7e8b41"></a><a name="section-4.8"></a><p></p>
<h2>Nervous System</h2>
<p class="First">Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span>, craniotomy, or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ecb4642-9318-45a4-9d86-bd8a5926ed41"></a><a name="section-4.9"></a><p></p>
<h2>Ophthalmic Diseases</h2>
<p class="First">Sympathetic ophthalmia, <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and ocular inflammatory conditions unresponsive to topical corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96323d40-90ac-45c6-9fc8-10a45f25a79f"></a><a name="section-4.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Diseases</span></h2>
<p class="First">To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6cfeb10-231c-441b-8779-1f8de5834712"></a><a name="section-4.11"></a><p></p>
<h2>Respiratory Diseases</h2>
<p class="First">Berylliosis, fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy, idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>, symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7a5d3a7-94c7-4209-9a29-a12b8b53a0fb"></a><a name="section-4.12"></a><p></p>
<h2>Rheumatic Disorders</h2>
<p class="First">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, acute rheumatic carditis, <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy). For the treatment of <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1cab7fb9-c814-47ad-a601-95d509703617"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Contraindicated in systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (see : ) and patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product and its consituents.
                            <a href="#i4i_warnings_id_677bdaff-c20f-4fe0-9be6-696a8c76e561">WARNINGS</a><a href="#i4i_section_id_bb3757df-ac33-45ff-9436-8e94b97c1a09"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></a></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_677bdaff-c20f-4fe0-9be6-696a8c76e561"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c64a29a9-fc44-466c-888e-5ac69adca949"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy (see ).
                                    <a href="#i4i_adverse_effects_id_022bbcb3-a574-4f54-8ec2-2204a9af2d59">ADVERSE REACTIONS</a></p>
<p>Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4d7f5a7-ca55-4a16-942e-a1fd3b075b71"></a><a name="section-6.2"></a><p></p>
<h2>Cardio-Renal</h2>
<p class="First">Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aaf5547a-ed9f-4834-9252-c0fab01e2947"></a><a name="section-6.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de9664ea-0e64-4090-916b-9b90de125753"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0c8fadb-e26d-412c-b1f9-339453b8e5f8"></a><a name="section-6.4.1"></a><p></p>
<h3>General</h3>
<p class="First">Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than are healthy individuals. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb3757df-ac33-45ff-9436-8e94b97c1a09"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h3>
<p class="First">Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control life-threatening drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see : : ).
                                            <a href="#i4i_precautions_id_97d03bc2-0436-4d95-a418-f7ea3568c1c3">PRECAUTIONS</a><a href="#i4i_interactions_id_2c73cba0-56b1-4955-adc9-32c9300f6964">Drug Interactions</a><a href="#i4i_section_id_91292cd4-1d27-47ff-a067-642dbdb7d301">Amphotericin B injection and potassium-depleting agents</a></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54194c8e-9ba6-4e0e-a55a-4993d32912e3"></a><a name="section-6.4.3"></a><p></p>
<h3>Special Pathogens</h3>
<p class="First">Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by , , , , , , .
                                            <span class="Italics">Amoeba</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span><span class="Italics">Cryptococcus</span><span class="Italics">Mycobacterium</span><span class="Italics">Nocardia</span><span class="Italics">Pneumocystis</span><span class="Italics">Toxoplasma</span></p>
<p>It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a39103d6-bcff-47c3-a8c6-6b01b631a3f4"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h3>
<p class="First">The use of corticosteroids in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64f5f161-0586-4eb9-9489-6a423899f067"></a><a name="section-6.4.5"></a><p></p>
<h3>Vaccination</h3>
<p class="First">Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.
                                            <span class="Bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb096ee1-4b9e-4db1-92a3-4479eb869b86"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immune globulin (IG) may be indicated. (See the respective package inserts for VZIG and IG for complete prescribing information.) If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73881010-6af8-409b-a368-5877dfa22e34"></a><a name="section-6.5"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_97d03bc2-0436-4d95-a418-f7ea3568c1c3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1420b32d-33a4-4476-9b01-233be0f1c4d4"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc728c05-c04f-472a-b397-f76853675a9d"></a><a name="section-7.2"></a><p></p>
<h2>Cardio-Renal</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ccb71c05-2aa7-46ca-9ec5-acd6752696ef"></a><a name="section-7.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb4963c6-e8ad-41f9-a818-d2a01973940a"></a><a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Steroids should be used with caution in active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, since they may increase the risk of a perforation.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent.</p>
<p>There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_baa75dc9-641f-4521-991a-878d2d68323c"></a><a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (e.g., postmenopausal women) before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb44c80e-0c06-4a72-b5db-ba25b536e2bc"></a><a name="section-7.6"></a><p></p>
<h2>Neuro-Psychiatric</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See .)
                                    <a href="#i4i_section_id_1ea7f347-4c61-469b-a0ec-f196ef4c210b">DOSAGE AND ADMINISTRATION</a></p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26c20f6a-73d2-4b52-ad8a-897287d58b62"></a><a name="section-7.7"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">lntraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7f29c7ec-e767-46ff-9171-c5dfd40f224d"></a><a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision. As prolonged use may cause <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and make patients dependent on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an acute illness including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the <span class="product-label-link" type="condition" conceptid="4224791" conceptname="Steroid withdrawal syndrome">corticosteroid withdrawal syndrome</span> including, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p>Persons who are on corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_2c73cba0-56b1-4955-adc9-32c9300f6964"></a><a name="section-7.9"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f5a0d61-9111-44b7-875f-bb5bf7052a63"></a><a name="section-7.9.1"></a><p></p>
<h3>Aminoglutethimide</h3>
<p class="First">Aminoglutethimide may diminish adrenal suppression by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91292cd4-1d27-47ff-a067-642dbdb7d301"></a><a name="section-7.9.2"></a><p></p>
<h3>Amphotericin B injection and potassium-depleting agents</h3>
<p class="First">When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8aa8fd0d-0da6-4161-8f0e-4682284b2b70"></a><a name="section-7.9.3"></a><p></p>
<h3>Antibiotics</h3>
<p class="First">Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions: Hepatic Enzyme Inducers, Inhibitors and Substrates).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56b1869c-2c1b-4123-a605-8ccd98bbe2ae"></a><a name="section-7.9.4"></a><p></p>
<h3>Anticholinesterases</h3>
<p class="First">Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_087ef853-0518-4340-b1bb-f208e7da4229"></a><a name="section-7.9.5"></a><p></p>
<h3>Anticoagulants, Oral</h3>
<p class="First">Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7869c676-b036-4115-b1a8-afe0f245edb0"></a><a name="section-7.9.6"></a><p></p>
<h3>Antidiabetics</h3>
<p class="First">Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8f88d9e-f467-4a8b-b919-9d33efd9286b"></a><a name="section-7.9.7"></a><p></p>
<h3>Antitubercular Drugs</h3>
<p class="First">Serum concentrations of isoniazid may be decreased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a63fd9d-bbfb-4e6c-b5c6-f8a976fcb09c"></a><a name="section-7.9.8"></a><p></p>
<h3>Cholestyramine</h3>
<p class="First">Cholestyramine may increase the clearance of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_597ded6b-c2be-4117-ae18-a4a57a407296"></a><a name="section-7.9.9"></a><p></p>
<h3>Cyclosporine</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95e8b09d-029c-4990-8f52-42dcee10fb09"></a><a name="section-7.9.10"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">Dexamethasone Suppression Test</span> (DST)</h3>
<p class="First">False-negative results in the <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_45fbc95f-bfc6-48ed-b66e-02c868a3a98b"></a><a name="section-7.9.11"></a><p></p>
<h3>Digitalis Glycosides</h3>
<p class="First">Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3f7c6d6-2c6f-43a7-8c59-e0cfc2957613"></a><a name="section-7.9.12"></a><p></p>
<h3>Ephedrine</h3>
<p class="First">Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bfca29c-4ae4-495c-b31e-47a0ba02917b"></a><a name="section-7.9.13"></a><p></p>
<h3>Estrogens, including Oral Contraceptives</h3>
<p class="First">Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94ccc377-9ed7-46ea-9e6c-f29678bb2e18"></a><a name="section-7.9.14"></a><p></p>
<h3>Hepatic Enzyme Inducers, Inhibitors and Substrates</h3>
<p class="First">Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity ( ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 ( ) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-adminstration with other drugs that are metabolized by CYP 3A4 ( ) may increase their clearance, resulting in decreased plasma concentration.
                                            <span class="Italics">e.g., barbiturates, phenytoin, carbamazepine, rifampin</span><span class="Italics">e.g., ketoconazole, macrolide antibiotics such as erythromycin</span><span class="Italics">e.g., indinavir, erythromycin</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec8ffc4c-d44a-41f3-92df-0803d1294fd7"></a><a name="section-7.9.15"></a><p></p>
<h3>Ketoconazole</h3>
<p class="First">Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> during corticosteroid withdrawal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a74dd27e-2ddb-4c48-9058-a8b876fb2b2b"></a><a name="section-7.9.16"></a><p></p>
<h3>Nonsteroidal Anti-Inflammatory Agents (NSAIDS)</h3>
<p class="First">Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_407495a1-8c6f-4169-895d-dcea6c25e46b"></a><a name="section-7.9.17"></a><p></p>
<h3>Phenytoin</h3>
<p class="First">In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1a63cb5-b6c4-42f2-9286-a12655061067"></a><a name="section-7.9.18"></a><p></p>
<h3>Skin Tests</h3>
<p class="First">Corticosteroids may suppress reactions to skin tests.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ab4fcc0-0e08-4627-bfdd-50c97d68e180"></a><a name="section-7.9.19"></a><p></p>
<h3>Thalidomide</h3>
<p class="First">Co-administration with thalidomide should be employed cautiously, as <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> has been reported with concomitant use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c5a9439-18e6-4a49-a52c-f3ed72e826ef"></a><a name="section-7.9.20"></a><p></p>
<h3>Vaccines</h3>
<p class="First">Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see : : ).
                                            <a href="#i4i_warnings_id_677bdaff-c20f-4fe0-9be6-696a8c76e561">WARNINGS</a><a href="#i4i_section_id_de9664ea-0e64-4090-916b-9b90de125753"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a><a href="#i4i_section_id_64f5f161-0586-4eb9-9489-6a423899f067">Vaccination</a></p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_649d1740-11c8-4c5c-9807-c7342072c2b8"></a><a name="section-7.10"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_245ef783-cc1b-428d-8f89-8b09a34fdd95"></a><a name="section-7.11"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ad323b8-af5a-4bcd-a441-2db3d2e478fb"></a><a name="section-7.11.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fb8864a-a151-4b47-b78f-a943d2166404"></a><a name="section-7.11.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0c5adae5-80bf-4a30-a91a-e97e369f85cc"></a><a name="section-7.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ae170d6e-e627-42fa-89f7-64d2b33f456b"></a><a name="section-7.13"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (patients &gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (patients &gt;1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.</p>
<p>The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be to the lowest effective dose.
                                    <a href="#i4i_adverse_effects_id_022bbcb3-a574-4f54-8ec2-2204a9af2d59">ADVERSE REACTIONS</a><span class="Italics">titrated</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_b5de2ec8-4979-4433-9349-27c9d6b4baff"></a><a name="section-7.14"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, the increased risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in elderly patients treated with corticosteroids should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_022bbcb3-a574-4f54-8ec2-2204a9af2d59"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">(listed alphabetically, under each subsection)</span></p>
<p>The following adverse reactions have been reported with dexamethasone or other corticosteroids:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea886974-c7f9-4dc1-b54e-2bd765002a66"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ecf6275-92c2-4a65-9a06-515c79ce01c4"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see : ), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.
                                    <a href="#i4i_warnings_id_677bdaff-c20f-4fe0-9be6-696a8c76e561">WARNINGS</a><a href="#i4i_section_id_b4d7f5a7-ca55-4a16-942e-a1fd3b075b71">Cardio-Renal</a></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af673f78-e5dd-4de4-a29d-ba527dd5abda"></a><a name="section-8.3"></a><p></p>
<h2>Dermatologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4221900f-a21e-4856-9c76-fe514b78287a"></a><a name="section-8.4"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Decreased carbohydrate and glucose tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, increased requirements for insulin or oral hypoglycemic agents in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ada97711-3118-4ccb-872b-2accb67d8928"></a><a name="section-8.5"></a><p></p>
<h2>Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe9178c7-6641-4d8b-b6a8-2419cd86a038"></a><a name="section-8.6"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, elevation in serum liver enzyme levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2db09bd-c3e6-4630-a4a3-dd44f539cc86"></a><a name="section-8.7"></a><p></p>
<h2>Metabolic</h2>
<p class="First">Negative nitrogen balance due to protein catabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf2c74aa-ba2f-4649-84c9-925b1485b0c9"></a><a name="section-8.8"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7039312c-ea65-4e42-b2b1-e2a352084fce"></a><a name="section-8.9"></a><p></p>
<h2>Neurological/Psychiatric</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, psychic disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d891a078-6bde-40f3-a454-bd5bb3767aec"></a><a name="section-8.10"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d283a06-ebe3-4311-99fa-400fe1030a5f"></a><a name="section-8.11"></a><p></p>
<h2>Other</h2>
<p class="First">Abnormal fat deposits, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_0bc8b006-9b30-41c3-be80-5079cae7d828"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Treatment of overdosage is by supportive and symptomatic therapy. In the case of acute overdosage, according to the patient's condition, supportive therapy may include gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ea7f347-4c61-469b-a0ec-f196ef4c210b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c43c33a4-9e8b-4724-901e-460ab77a2084"></a><a name="section-10.1"></a><p></p>
<h2>For Oral Administration</h2>
<p class="First">The initial dosage varies from 0.75 to 9 mg a day depending on the disease being treated.</p>
<p><span class="Italics">It Should Be Emphasized That Dosage Requirements Are Variable And Must Be Individualized On The Basis Of The Disease Under Treatment And The Response Of The Patient.</span></p>
<p>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached.</p>
<p>Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 30 mg of dexamethasone for a week followed by 4 to 12 mg every other day for one month have been shown to be effective (see : ).
                                    <a href="#i4i_precautions_id_97d03bc2-0436-4d95-a418-f7ea3568c1c3">PRECAUTIONS</a><a href="#i4i_section_id_cb44c80e-0c06-4a72-b5db-ba25b536e2bc">Neuro-Psychiatric</a></p>
<p>In pediatric patients, the initial dose of dexamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m bsa/day).
                                    <span class="Sup">2</span></p>
<a name="id_260e7ceb-0467-41b2-bcd3-fb0ad9f41de8"></a><table width="0.000">
<caption><span>For the purpose of comparison, the following is the equivalent milligram dosage of the various corticosteroids:</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">Cortisone, 25</td>
<td align="center" valign="top">Triamcinolone, 4</td>
</tr>
<tr>
<td align="center" valign="top">Hydrocortisone, 20</td>
<td align="center" valign="top">Paramethasone, 2</td>
</tr>
<tr>
<td align="center" valign="top">Prednisolone, 5</td>
<td align="center" valign="top">Betamethasone, 0.75</td>
</tr>
<tr>
<td align="center" valign="top">Prednisone, 5</td>
<td align="center" valign="top">Dexamethasone, 0.75</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Methylprednisolone, 4</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Italics">These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</span></p>
<p>the following dosage schedule combining parenteral and oral therapy is suggested:
                                    <span class="Italics">In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders,</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a83e57b-1431-48d8-ac44-7bdb004ffafe"></a><a name="section-10.2"></a><p></p>
<h2>Dexamethasone sodium phosphate injection, 4 mg per mL</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e1c6344-aada-4a0b-b91d-66a8b65494cf"></a><a name="section-10.2.1"></a><p></p>
<h3>First Day</h3>
<p class="First">1 or 2 mL, intramuscularly</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87dc9c2d-b018-4ad2-abfd-884104755057"></a><a name="section-10.3"></a><p></p>
<h2>Dexamethasone tablets, 0.75 mg</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f34b3169-76fc-45ab-8ea3-66fb2b7afd0b"></a><a name="section-10.3.1"></a><p></p>
<h3>Second Day</h3>
<p class="First">4 tablets in two divided doses</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1f338fc-1200-407d-8a22-a51d6928ba01"></a><a name="section-10.3.2"></a><p></p>
<h3>Third Day</h3>
<p class="First">4 tablets in two divided doses</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_403f18a1-e474-4892-8fed-defa6a60cf70"></a><a name="section-10.3.3"></a><p></p>
<h3>Fourth Day</h3>
<p class="First">2 tablets in two divided doses</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b3fb4cf-e5c7-4868-b314-abf95ba9e304"></a><a name="section-10.3.4"></a><p></p>
<h3>Fifth Day</h3>
<p class="First">1 tablet</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6eb00e2-3dd5-4ad8-918b-a154dcc99c60"></a><a name="section-10.3.5"></a><p></p>
<h3>Sixth Day</h3>
<p class="First">1 tablet</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ea6fbdc-d4fd-446e-9aa5-b0a6b3c2a479"></a><a name="section-10.3.6"></a><p></p>
<h3>Seventh Day</h3>
<p class="First">No treatment</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a58d7400-0e88-467e-bad8-183133786a31"></a><a name="section-10.3.7"></a><p></p>
<h3>Eighth Day</h3>
<p class="First">Follow-up visit</p>
<p>This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.</p>
<p>In , dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by 4 mg every six hours intramuscularly until the symptoms of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span>, maintenance therapy with either dexamethasone sodium phosphate injection or dexamethasone tablets in a dosage of 2 mg two or three times daily may be effective.
                                            <span class="Italics"><span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa2867cb-b37b-4761-8ec4-1e84ecac677b"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">Dexamethasone Suppression Tests</span></h2>
<ol>
<li>Tests for Cushing’s syndrome
                                        <p class="First">Give 1.0 mg of dexamethasone orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning.</p>
<p>For greater accuracy, give 0.5 mg of dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.</p>
</li>
<li>Test to distinguish Cushing’s syndrome due to pituitary ACTH excess from Cushing’s syndrome due to other causes.
                                        <p class="First">Give 2.0 mg of dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.</p>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c217fa2c-3880-49eb-aea5-62083042a33c"></a><a name="section-10.5"></a><p></p>
<h2>Proper Use of an Intensol™</h2>
<p class="First">An Intensol is a concentrated oral solution as compared to standard oral liquid medications. It is recommended that an Intensol be mixed with liquid or semi-solid food such as water, juices, soda or soda-like beverages, applesauce and puddings.</p>
<p>Use only the calibrated dropper provided with this product. Draw into the dropper the amount prescribed for a single dose. Then squeeze the dropper contents into a liquid or semi-solid food. Stir the liquid or food gently for a few seconds. The Intensol formulation blends quickly and completely. The entire amount of the mixture, of drug and liquid or drug and food, should be consumed immediately. Do not store for future use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2a5c85a8-e2ad-4592-9c38-439d1a486cf3"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-5026-4 in a PACKAGE of 1 SOLUTION, CONCENTRATES</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f7796ab-3493-4979-a35f-c0777eb15685"></a><a name="section-11.1"></a><p></p>
<h2>Dexamethasone Tablets USP:</h2>
<p class="First"><span class="Bold">0.5 mg yellow, scored tablets (Identified 54 299).</span></p>
<p>NDC 0054-8179-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4179-25: Bottles of 100 tablets.</p>
<p><span class="Bold">0.75 mg <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> blue, scored tablet (Identified 54 960).</span></p>
<p>NDC 0054-8180-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4180-25: Bottles of 100 tablets.</p>
<p><span class="Bold">1 mg yellow, scored tablets (Identified 54 489).</span></p>
<p>NDC 0054-8174-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4181-25: Bottles of 100 tablets.</p>
<p><span class="Bold">1.5 mg pink, scored tablets (Identified 54 943).</span></p>
<p>NDC 0054-8181-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4182-25: Bottles of 100 tablets.</p>
<p>NDC 0054-4182-31: Bottles of 1000 tablets.</p>
<p><span class="Bold">2 mg white, scored tablets (Identified 54 662).</span></p>
<p>NDC 0054-8176-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4183-25 Bottles of 100 tablets.</p>
<p><span class="Bold">4 mg green, scored tablets (Identified 54 892).</span></p>
<p>NDC 0054-8175-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4184-25: Bottles of 100 tablets.</p>
<p><span class="Bold">6 mg aqua, scored tablets (Identified 54 769).</span></p>
<p>NDC 0054-8183-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.</p>
<p>NDC 0054-4186-25: Bottles of 100 tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f15e6b82-1feb-495e-9c0a-5fcfc58933bf"></a><a name="section-11.1.1"></a><p></p>
<h3>Store and Dispense:</h3>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a well-closed, light-resistant container as defined in the USP/NF.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53316944-01ad-4e59-b8cf-7389c504a7af"></a><a name="section-11.2"></a><p></p>
<h2>Dexamethasone Oral Solution, 0.5 mg per 5 mL:</h2>
<p class="First">NDC 0054-3177-57: Bottles of 240 mL.</p>
<p>NDC 0054-3177-63: Bottles of 500 mL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75319b53-6e60-4e6a-a7d2-225d64f08faa"></a><a name="section-11.2.1"></a><p></p>
<h3>Store and Dispense:</h3>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP/NF.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f77b34ae-472b-4c3c-951d-eee8ad07c859"></a><a name="section-11.3"></a><p></p>
<h2>Dexamethasone Intensol ™ Oral Solution (Concentrate), 1 mg per mL:</h2>
<p class="First">NDC 0054-3176-44: Bottles of 30 mL with calibrated dropper [graduations of 0.25 mL (0.25 mg), 0.5 mL (0.5 mg), 0.75 mL (0.75 mg), and 1 mL (1 mg), on the dropper].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f1213b1-e634-4dc9-91d8-7f75163c6008"></a><a name="section-11.3.1"></a><p></p>
<h3>Store and Dispense:</h3>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Do not use if solution contains a precipitate. Dispense only in this bottle and only with the calibrated dropper provided. Discard opened bottle after 90 days.</p>
<p><span class="Bold">4047401//04</span></p>
<p><span class="Bold">Revised September 2007</span></p>
<p>© RLI, 2007</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Dexamethasone (Intensol) 1MG/1ML</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a817ab46-54ec-4e3f-886b-04ce6ac1caf9&amp;name=68151-5026.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXAMETHASONE INTENSOL 		
					</strong><br><span class="contentTableReg">dexamethasone intensol solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-5026(NDC:0054-3176)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXAMETHASONE</strong> (DEXAMETHASONE) </td>
<td class="formItem">DEXAMETHASONE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZOIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-5026-4</td>
<td class="formItem">1 mL in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088252</td>
<td class="formItem">09/01/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-5026)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>38554d9e-d106-4280-9c55-685a5d076f55</div>
<div>Set id: a817ab46-54ec-4e3f-886b-04ce6ac1caf9</div>
<div>Version: 2</div>
<div>Effective Time: 20090831</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
